SCHEMBL651038

SCHEMBL651038

Cc1ccc(/N=C2/NC(=O)/C(=C/c3cnc(NC(=O)C4CCN(C)CC4)s3)S2)c(C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
NPSR1 Q6W5P4 4/20 0.50
LMNA P02545 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
MAPK1 P28482 1/20 0.50
RECQL P46063 1/20 0.49
POLB P06746 1/20 0.47
HPGD P15428 1/20 0.47
MKNK1 Q9BUB5 1/20 0.43
RNASEL Q05823 1/20 0.41
GSK3B P49841 5/20 0.41
DYRK1A Q13627 5/20 0.41
WNT1 P04628 3/20 0.41
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ABL1 P00519 3/20 0.38
LCK P06239 1/20 0.38
OGA O60502 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL652132 0.94 MAPT (0.55) MAPTNPSR1LMNATDP1L3MBTL1
SCHEMBL651049 0.93 MKNK1 (0.42) MAPTNPSR1LMNATDP1L3MBTL1
SCHEMBL650931 0.92 MKNK1 (0.42) MAPTNPSR1LMNATDP1L3MBTL1
SCHEMBL697898 0.91 MAPT (0.43) MAPTNPSR1LMNATDP1L3MBTL1
SCHEMBL651160 0.88 MAPT (0.51) MAPTNPSR1LMNATDP1L3MBTL1
SCHEMBL10176480 0.88 MAPT (0.41) MAPTNPSR1LMNATDP1L3MBTL1
SCHEMBL650007 0.87 MKNK1 (0.43) POLBMKNK1RNASELGSK3BDYRK1A
SCHEMBL10227590 0.87 MAPT (0.46) MAPTNPSR1LMNATDP1L3MBTL1
SCHEMBL652061 0.86 MAPT (0.56) MAPTNPSR1LMNATDP1L3MBTL1
SCHEMBL652062 0.86 MAPT (0.56) MAPTNPSR1LMNATDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
WO-2010122979-A1 THIAZOLIDINONE DERIVATIVE SBIバイオテック株式会社 (JP) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 MAPT 3657/4885NPSR1 4464/4885LMNA 3772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.